Skip to main content

Adalimumab Drug Levels Predict Efficacy

Jul 05, 2015 11:01 pm

In a prospective study of 311 rheumatoid arthritis patients starting either adalimumab (ADA) or etanercept, investigators sought to correlate drug levels and/or anti-drug antibodies with clinical outcomes (citation source  ADA levels best predicted DAS28 at 12 months (R= 0.060) and low drug levels were associated with BMI > 30 and nonadherence. Anti-ADA drug antibody formation and low ADA levels were best at predicting the EULAR response at 12 months (see video). 

The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.